INBX · Inhibrx Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
Market Cap
1.019B
52 Wk Range
$57.30 - $155.29
Previous Close
$74.33
Open
$72.72
Volume
252,128
Day Range
$68.78 - $74.60
Enterprise Value
1.18B
Cash
199.5M
Avg Qtr Burn
-34.61M
Insider Ownership
23.00%
Institutional Own.
91.79%
Qtr Updated
Sep 30th 2026
